Published by
The Street
The Street
By PR Newswire SHANGHAI and HONG KONG, Dec. 17, 2021 /PRNewswire/ — Antengene Corporation Limited (the “Company” or “Antengene”) is pleased to announce that ATG-010 (selinexor, brand name: XPOVIO ®), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound has received conditional approval for marketing by the National Medical Products Administration(the “NMPA”), applicable in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received prior therapy including a proteasome inhibitor, an immunomodulatory ag…